Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;22(12):761-776.
doi: 10.2217/pgs-2021-0032. Epub 2021 Sep 1.

Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models

Judith Hayward  1   2 , John McDermott  3   4 , Nadeem Qureshi  5 , William Newman  3   4
Affiliations
Review

Pharmacogenomic testing to support prescribing in primary care: a structured review of implementation models

Judith Hayward et al. Pharmacogenomics. 2021 Aug.

Abstract

The application of pharmacogenomics could meaningfully contribute toward medicines optimization within primary care. This review identified 13 studies describing eight implementation models utilizing a multi-gene pharmacogenomic panel within a primary care or community setting. These were small feasibility studies (n <200). They demonstrated importance and feasibility of pre-test counseling, the role of the pharmacist, data integration into the electronic medical record and point-of-care clinical decision support systems (CDSS). Findings were considered alongside existing primary care prescribing practices and implementation frameworks to demonstrate how issues may be addressed by existing nationalized healthcare and primary care infrastructure. Development of point-of-care CDSS should be prioritized; establishing clinical leadership, education programs, defining practitioner roles and responsibilities and addressing commissioning issues will also be crucial.

Keywords: community; implementation; medicines optimization; pharmacogenomics; prescribing; primary care.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

J Hayward was supported by University of Manchester and Health Education England Genomics Education Programme. The work of WG Newman is supported by the Manchester NIHR BRC (IS-BRC-1215-20007). J Hayward has a non-remunerated role with Congenica. The authors would like to thank North West Genomics Medicine Service Alliance for supporting this work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1.
Figure 1.. Study selection process to determine papers describing implementation models for PGx via panel testing within primary care.
See this image and copyright information in PMC

References

    1. Pirmohamed M. Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu. Rev. Genomics Hum. Genet. 15(1), 349–370 (2014). - PubMed
    1. Swen JJ, Huizinga TW, Gelderblom Het al.Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med. 4(8), e209 (2007). - PMC - PubMed
    1. Pirmohamed M, Burnside G, Eriksson Net al.A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med. 369(24), 2294–2303 (2013). - PubMed
    1. Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J. Clin. Med. 9(1), 22 (2019). - PMC - PubMed
    1. Swen J, Wilting I, de Goede Aet al.Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 83(5), 781–787 (2008). - PubMed

Publication types

MeSH terms

LinkOut - more resources